AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21973 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 523
Study 7138751 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol SA 200 mg
Number of subjects: 8
Study 7138751 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol SR 200 mg
Number of subjects: 8
Study 7138751 — intervention group
Group type: COMPARATOR
Intervention: Conventional Metoprolol 200 mg
Number of subjects: 8
Study 7138751 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8
Study 31204321 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA with smear layer (Group 1)
Number of subjects: 40
Study 31204321 — intervention group
Group type: COMPARATOR
Intervention: MTA without smear layer (Group 2)
Number of subjects: 40
Study 30424742 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention combining behavioural support, nicotine replacement therapy, and personalized feedback on home air quality
Number of subjects: 205
Study 30424742 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 26228466 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (90 min once weekly for 10 weeks)
Number of subjects: 54
Study 26228466 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 54
Study 26228466 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study 24013269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group-based intervention (five sessions, n = 41)
Number of subjects: 82
Study 24013269 — intervention group
Group type: COMPARATOR
Intervention: Control group (three informative sessions, n = 41)
Number of subjects: 82
Study 23176560 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly motivation feedback generated by clinicians (additional to treatment as usual)
Number of subjects: 350
Study 23176560 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 350
Study 20840175 — intervention group
Group type: EXPERIMENTAL
Intervention: Change talk 'towards change' at the end of the BMI
Number of subjects: 97
Study 20840175 — intervention group
Group type: COMPARATOR
Intervention: Change talk 'away from change'
Number of subjects: 97
Study 16740247 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration alarms
Number of subjects: 85
Study 16740247 — intervention group
Group type: COMPARATOR
Intervention: Short-duration alarms
Number of subjects: 85
Study 16740247 — intervention group
Group type: EXPERIMENTAL
Intervention: Short- and long-duration alarms from unique systems
Number of subjects: 85
Study 15721974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group training (CBGT) for patients with type 1 diabetes
Number of subjects: 7
Study 15721974 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7
Study 12361444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (n = 82)
Number of subjects: 162
Study 12361444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 80)
Number of subjects: 162
Study 10102409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 10
Study 10102409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7789486 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of BAY u 3405 (TP receptor antagonist)
Number of subjects: 12
Study 7789486 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of BAY u 3405 (TP receptor antagonist)
Number of subjects: 12
Study 7789486 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of BAY u 3405 (TP receptor antagonist)
Number of subjects: 12
Study 7789486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2189866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (oral administration for 3 months)
Number of subjects: 40
Study 2189866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (continued in open study for 15-18 months)
Number of subjects: 40
Study 2189866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 111472 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microgram of synthetic TRH
Number of subjects: 12
Study 111472 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microgram of synthetic LRH
Number of subjects: 12
Study 111472 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 12
Study 31294917 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional risk factors only (age, sex, smoking, type 2 diabetes mellitus)
Number of subjects: 1811
Study 31294917 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional risk factors and eleven new factors (including polypharmacy and apathy symptoms)
Number of subjects: 1811
Study 31294917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox-regression model including traditional and new factors
Number of subjects: 1811
Study 31294917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox-regression model accounting for competing risks
Number of subjects: 1811
Study 31294917 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional risk factors (SBP, HDL, total cholesterol)
Number of subjects: 1811
Study 27892839 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse Tetric N‐Bond (Ivoclar Vivadent) with incremental technique
Number of subjects: 236
Study 27892839 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse Tetric N‐Bond (Ivoclar Vivadent) with bulk-fill technique
Number of subjects: 236
Study 27892839 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etch Tetric N‐Bond SE (Ivoclar Vivadent) with incremental technique
Number of subjects: 236
Study 27892839 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etch Tetric N‐Bond SE (Ivoclar Vivadent) with bulk-fill technique
Number of subjects: 236
Study 25861158 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (11 mA)
Number of subjects: 20
Study 25861158 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 23324510 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing of insulin glargine (0.5 units/kg)
Number of subjects: 200
Study 23324510 — intervention group
Group type: COMPARATOR
Intervention: Percentage-based dosing of insulin glargine (50% of TDI)
Number of subjects: 200
Study 21318594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (84 μg)
Number of subjects: 6
Study 21318594 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (84 μg)
Number of subjects: 6
Study 19545476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 24
Study 19545476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17383417 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoscopy with endomicroscopy
Number of subjects: 161
Study 17383417 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 161
Study 17383417 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomicroscopy
Number of subjects: 161
Study 15326071 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 20
Study 15326071 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA+EVBT (14 Gy by gamma‐irradiation source)
Number of subjects: 20
Study 15326071 — intervention group
Group type: COMPARATOR
Intervention: PTA+EVBT
Number of subjects: 20
Study 11312459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine plain
Number of subjects: 40
Study 11312459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with 1:200,000 epinephrine
Number of subjects: 40
Study 11312459 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 40
Study 9460345 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-targeted therapies
Number of subjects: 24
Study 8496768 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-miscible form of vitamin E
Number of subjects: 27
Study 8496768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-soluble form of vitamin E
Number of subjects: 27
Study 3440774 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 g doses of cefonicid followed by ethanol challenges
Number of subjects: 15
Study 3440774 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by ethanol challenges
Number of subjects: 15
Study 3440774 — intervention group
Group type: EXPERIMENTAL
Intervention: Three consecutive 1 g doses of cefonicid given at 24 h intervals followed by ethanol challenge
Number of subjects: 15
Study 31144363 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL)
Number of subjects: 129
Study 31144363 — intervention group
Group type: COMPARATOR
Intervention: Teaching sequences (not specified)
Number of subjects: 129
Study 28243022 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative IOP adjustment
Number of subjects: 135
Study 28243022 — intervention group
Group type: COMPARATOR
Intervention: Normal IOP (16 to 21 mmHg)
Number of subjects: 135
Study 28243022 — intervention group
Group type: COMPARATOR
Intervention: Low IOP (<16 mmHg)
Number of subjects: 135
Study 28243022 — intervention group
Group type: COMPARATOR
Intervention: Elevated IOP (>21 to 30 mmHg)
Number of subjects: 135
Study 28243022 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in IOP from operating theater to 1 day after surgery
Number of subjects: 135
Study 25964168 — intervention group
Group type: EXPERIMENTAL
Intervention: Live virus zoster vaccine (ZV)
Number of subjects: 0
Study 25964168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22956195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous ammonium phosphate (FAP)
Number of subjects: 38
Study 22956195 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (reference compound)
Number of subjects: 38
Study 22956195 — intervention group
Group type: COMPARATOR
Intervention: Ferric pyrophosphate (FPP)
Number of subjects: 38
Study 22956195 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FAP to FPP
Number of subjects: 38
Study 22956195 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FAP to ferrous sulfate
Number of subjects: 38
Study 22956195 — intervention group
Group type: COMPARATOR
Intervention: Relative bioavailability of FAP and FPP compared to ferrous sulfate
Number of subjects: 38
Study 21381017 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg/kg daily G‐CSF
Number of subjects: 46
Study 21381017 — intervention group
Group type: COMPARATOR
Intervention: 10 μg/kg daily G‐CSF
Number of subjects: 46
Study 19298563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 1520
Study 19298563 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OPT)
Number of subjects: 1520
Study 16448563 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal overjet (Class I)
Number of subjects: 84
Study 16448563 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased overjet (Class II)
Number of subjects: 84
Study 16448563 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed overjet (Class III)
Number of subjects: 84
Study 16448563 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 84
Study 16448563 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 84
Study 12953125 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I-M195 or (131)I-HuM195 (122-437 mCi) plus busulfan (16 mg/kg) and cyclophosphamide (90-120 mg/kg)
Number of subjects: 31
Study 10711488 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-size self-inflatable bag (maximum volume, 1100 ml)
Number of subjects: 50
Study 8622323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (50 mg/kg intravenously)
Number of subjects: 88
Study 8622323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 88
Study 8622323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (50 mg/kg intravenously) in children with cyanosis
Number of subjects: 88
Study 8622323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) in children with cyanosis
Number of subjects: 88
Study 8622323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid in children with cyanosis
Number of subjects: 88
Study 8622323 — intervention group
Group type: COMPARATOR
Intervention: Placebo in children with cyanosis
Number of subjects: 88
Study 8622323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 88
Study 1419816 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA (100 mg/m2/d on days 7, 8, and 9)
Number of subjects: 155
Study 1419816 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy
Number of subjects: 155
Study 1419816 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (ara-C) (2-3 g/m2/12 h for 6 days)
Number of subjects: 155
Study 6366660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prostaglandin E2 vaginal pessaries (3 mg)
Number of subjects: 200
Study 6366660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prostaglandin E2 vaginal pessaries (0.5 mg)
Number of subjects: 200
Study 31790418 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional first-line drugs
Number of subjects: 582
Study 31790418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 582
Study 31790418 — intervention group
Group type: EXPERIMENTAL
Intervention: C3G (third-generation cephalosporins)
Number of subjects: 582
Study 31790418 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing isolates
Number of subjects: 582
Study 31790418 — intervention group
Group type: EXPERIMENTAL
Intervention: IncHI2 plasmid carrying blaCTX-M-15
Number of subjects: 582
Study 30234667 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published in 2016
Number of subjects: 395
Study 30234667 — intervention group
Group type: COMPARATOR
Intervention: RCTs published in 2010
Number of subjects: 395
Study 26036987 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based educational sessions delivered by community health workers in Spanish
Number of subjects: 116
Study 26036987 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 23351460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin level ≤0.6 mg/dl (group 1)
Number of subjects: 1135
Study 23351460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin level >0.6 to 1.2 mg/dl (group 2)
Number of subjects: 1135
Study 23351460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin level >1.2 mg/dl (group 3)
Number of subjects: 1135
Study 23351460 — intervention group
Group type: EXPERIMENTAL
Intervention: Log2 bilirubin (multivariate modeling)
Number of subjects: 1135
Study 21069380 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 32
Study 19690413 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplemented with Lactobacillus rhamnosus LB21 (10(7) CFU/ml) and 2.5 mg fluoride per litre for lunch
Number of subjects: 248
Study 19690413 — intervention group
Group type: COMPARATOR
Intervention: Standard milk
Number of subjects: 248
Study 19690413 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplemented with Lactobacillus rhamnosus LB21 and fluoride
Number of subjects: 248
Study 17459784 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention combining positive affect and self-affirmation
Number of subjects: 0
Study 17459784 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15669405 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting observations on a videotape of a confederate's performance
Number of subjects: 0
Study 11703224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (LDT)
Number of subjects: 15
Study 11703224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7960489 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine treatment, 200 mg per day for 7 days
Number of subjects: 35
Study 7960489 — intervention group
Group type: COMPARATOR
Intervention: Non supplemented (CF2 group)
Number of subjects: 35
Study 2958400 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms Hevac B vaccine at birth, 1, 2 and 14 months (Group I)
Number of subjects: 201
Study 2958400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms Hevac B vaccine at birth, 2 and 14 months (Group II)
Number of subjects: 201
Study 2958400 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms Hevac B vaccine (Group I)
Number of subjects: 201
Study 2958400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms Hevac B vaccine (Group II)
Number of subjects: 201
Study 2958400 — intervention group
Group type: COMPARATOR
Intervention: Comparison of anti-HBsAg positivity rates at birth
Number of subjects: 201
Study 2958400 — intervention group
Group type: COMPARATOR
Intervention: Comparison of seroconversion rates at 2 months
Number of subjects: 201
Study 29701040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy at the points detected with thermosensitive moxibustion in Zhuang medicine combined with western medication (methotrexate, salazosulfapyridine, hydroxychloroquine, meloxicam)
Number of subjects: 168
Study 29701040 — intervention group
Group type: COMPARATOR
Intervention: Western medication (methotrexate, salazosulfapyridine, hydroxychloroquine, meloxicam)
Number of subjects: 168
Study 27396518 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunisation at birth (n=54)
Number of subjects: 98
Study 27396518 — intervention group
Group type: COMPARATOR
Intervention: BCG immunisation at 2 months of age (n=44)
Number of subjects: 98
Study 26611343 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-otoscopy
Number of subjects: 60
Study 26611343 — intervention group
Group type: COMPARATOR
Intervention: Conventional otoscopy
Number of subjects: 60
Study 23902882 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunting during carotid endarterectomy (CEA)
Number of subjects: 180
Study 23902882 — intervention group
Group type: COMPARATOR
Intervention: No shunting during carotid endarterectomy (CEA)
Number of subjects: 180
Study 19035084 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel analgesic disposable Foley urinary catheter
Number of subjects: 200
Study 19035084 — intervention group
Group type: COMPARATOR
Intervention: Conventional F16 Foley urinary catheter
Number of subjects: 200
Study 17035649 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 314
Study 17035649 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention
Number of subjects: 314
Study 17035649 — intervention group
Group type: COMPARATOR
Intervention: Control group (quarterly newsletters)
Number of subjects: 314
Study 12791819 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-derived flow reserve (FR) measurement
Number of subjects: 10
Study 12791819 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 10
Study 12791819 — intervention group
Group type: COMPARATOR
Intervention: Plethysmography (PL)
Number of subjects: 10
Study 11034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal anuloplasty (IDTA)
Number of subjects: 53
Study 11034644 — intervention group
Group type: COMPARATOR
Intervention: Physical rehabilitation program (Control)
Number of subjects: 53
Study 9331910 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related brain activation (ERBA) during target detection
Number of subjects: 0
Study 9331910 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatio-temporal modelling of ERPs
Number of subjects: 0
Study 9331910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fMRI and EEG methods
Number of subjects: 0
Study 8365838 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock absorbing heel inserts (SAH)
Number of subjects: 91
Study 8365838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study 3466574 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 60 mg/m2
Number of subjects: 79
Study 3466574 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (DX) 40 mg/m2
Number of subjects: 79
Study 29308950 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise (CSE)
Number of subjects: 32
Study 29308950 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Awareness
Number of subjects: 32
Study 29308950 — intervention group
Group type: COMPARATOR
Intervention: Traditional Exercise (TE)
Number of subjects: 32
Study 26691428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 198
Study 26691428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 25038794 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic alone (Group A)
Number of subjects: 210
Study 25038794 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic plus supplement (Group B)
Number of subjects: 210
Study 23397246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Path Duo catheter (12-hole irrigated tip)
Number of subjects: 188
Study 20390374 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliosphere® bag (air-filled balloon, 960 cm3)
Number of subjects: 33
Study 20390374 — intervention group
Group type: COMPARATOR
Intervention: Bioenterics‐BIB® (saline-filled balloon, 700 ml)
Number of subjects: 33
Study 18216054 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy 160/4.5 microg twice daily and as needed
Number of subjects: 1538
Study 18216054 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 1538
Study 18216054 — intervention group
Group type: COMPARATOR
Intervention: Conventional best practice
Number of subjects: 1538
Study 15705992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator inhalation (400 mug salbutamol by metered-dose inhaler)
Number of subjects: 60
Study 15705992 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 60
Study 15705992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator inhalation
Number of subjects: 60